David T. Rubin

Active 1997–2025

Also published as
David T Rubin · David. T Rubin
269
Papers
28,637
Citations
88
h-index
246
i10-index

Citations

Citations per year for David T. Rubin1989: 2 citations1993: 1 citations1994: 1 citations1997: 2 citations1999: 7 citations2000: 16 citations2001: 17 citations2002: 22 citations2003: 19 citations2004: 38 citations2005: 30 citations2006: 31 citations2007: 36 citations2008: 51 citations2009: 28 citations2010: 50 citations2011: 52 citations2012: 72 citations2013: 83 citations2014: 89 citations2015: 99 citations2016: 154 citations2017: 198 citations2018: 207 citations2019: 693 citations2020: 981 citations2021: 1,063 citations2022: 1,201 citations2023: 1,166 citations2024: 2,001 citations2025: 1,203 citations2026: 25 citations1990–1992: no citations, so these years are not shown1995–1996: no citations, so these years are not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,528 citing papers, 20.2% of this breakdownChina: 1,166 citing papers, 9.3% of this breakdownUnited Kingdom: 857 citing papers, 6.8% of this breakdownItaly: 833 citing papers, 6.7% of this breakdownCanada: 778 citing papers, 6.2% of this breakdownFrance: 575 citing papers, 4.6% of this breakdownGermany: 498 citing papers, 4% of this breakdownNetherlands: 430 citing papers, 3.4% of this breakdownSpain: 371 citing papers, 3% of this breakdownJapan: 355 citing papers, 2.8% of this breakdownBelgium: 353 citing papers, 2.8% of this breakdownAustralia: 348 citing papers, 2.8% of this breakdown
0%20.2%Other 27.4%

Fields

  • Biochemistry, Genetics and Molecular Biology56.9%
  • Medicine31.6%
  • Immunology and Microbiology3.1%
  • Neuroscience2.8%
  • Computer Science1%
  • Agricultural and Biological Sciences0.9%
  • Other3.7%

Topics

  • Inflammatory Bowel Disease19.4%
  • Microscopic Colitis7.2%
  • Gut microbiota and health6.9%
  • Clostridium difficile and Clostridium perfringens research3.6%
  • Gastrointestinal motility and disorders2.8%
  • Rheumatoid Arthritis Research and Therapies2.8%
  • Other57.3%

Coauthors

All papers

Open in search
  1. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

    Authors: , , , , , , , , , , , , , , , , , , , - Gastroenterology 2021 cited by 2,666

  2. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management

    Authors: , , , - Gastroenterology 2021 cited by 826

  3. ACG Clinical Guideline: Ulcerative Colitis in Adults

    Authors: , , , , - The American Journal of Gastroenterology 2019 cited by 1,569

  4. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc Ferrante - The Lancet 2022 cited by 387

  5. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Silvio Danese, Julián Panés, Guillaume Bouguen, Sarah O’Donnell, Benjamin Pariente, Shawn Winer, Stephen B. Hanauer, J -F Colombel - The American Journal of Gastroenterology 2015 cited by 1,838

  6. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Geert D’Haens - The Lancet 2022 cited by 316

  7. Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yang Sun, Ida Hilmi, Raja Affendi Raja Ali, Mukesh S Paudel, Mansour Altuwaijri, Juanda Leo Hartono, Shu Chen Wei, Julajak Limsrivilai, Sara El Ouali, Beatriz Iade Vergara, Viet Hang Dao, Paul Kelly, Phoebe Hodges, Yinglei Miao, Maojuan Li - Clinical Gastroenterology and Hepatology 2022 cited by 272

  8. Increased Intestinal Permeability Is Associated With Later Development of Crohn’s Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gilaad G. Kaplan, Denis O. Krause, Karen Madsen, John Marshall, Paul Moayyedi, Mark J. Ropeleski, Ernest G. Seidman, Mark S. Silverberg, Scott B. Snapper, Andy Stadnyk, Hillary Steinhart, Michael G. Surette, Dan Turner, Thomas D. Walters, Bruce A. Vallance, Guy Aumais, Alain Bitton, Maria Cino, Jeff Critch, Lee A. Denson, Colette Deslandres, Wael El‐Matary, Hans Herfarth, Peter Higgins, Hien Q. Huynh, Jeff Hyams, David Mack, Jerry McGrath, Anthony Otley, Remo Panancionne, Guy Aumais, Robert N. Baldassano, Çharles N. Bernstein, Maria Cino, Lee A. Denson, Colette Deslandres, Wael El‐Matary, Anne M. Griffiths, Charlotte Hedin, Hans Herfarth, Peter Higgins, Séamus Hussey, Hien Hyams, Kevan Jacobson, David J. Keljo, David Kevans, Charlie W. Lees, David Mack, John Marshall, Jerry McGrath, Sanjay K. Murthy, Anthony Otley, Remo Panaccione, Nimisha Parekh, Sophie Plamondon, Graham Radford-Smith, Mark J. Ropeleski, Joel R. Rosh, David T. Rubin, Michael Schultz, Ernest G. Seidman, Corey A. Siegel, Scott B. Snapper, Hillary Steinhart, Dan Turner, Kenneth Croitoru - Gastroenterology 2020 cited by 310

  9. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

    Authors: , , , , , , - Gastroenterology 2017 cited by 426

  10. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

    Authors: , , , , , , , , , , , , , , , , , , , - Gastroenterology 2022 cited by 198

  11. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?

    Authors: , , - Gastroenterology 2022 cited by 187

  12. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , M Dubinsky, A Ekbom, P Fleshner, C Gasche, MA Gassull, R Gearry, S Ghosh, P Gibson, A Griffiths, J Halfvarson, S Hanauer, N Harpaz, A Hart, T Hibi, M Kamm, G Kaplan, A Kaser, B Korelitz, P Kotze, I Koutroubakis, W Kruis, P Lakatos, J Lewis, J Lindsay, E Loftus, E Louis, M Lukas, F Magro, U Mahadevan, G Mantzaris, J-Y Mary, D McGovern, B Moum, P Munkholm, M Neurath, S Ng, C O'Morain, T Oresland, R Panaccione, J Panes, Y Panis, J Pemberton, L Peyrin-Biroulet, C Prantera, D Rachmilewitz, Z Ran, W Reinisch, F Remzi, J Rhodes, R Riddell, G Rogler, D Rubin, D Sachar, W Sandborn, B Sands, B Sartor, J Schoelmerich, S Schreiber, C Siegel, B Siegmund, M Silverberg, J Söderholm, A Sood, A Spinelli, E Stange, F Steinwurz, S Targan, S Travis, D Turner, C Tysk and 5 more - ˜The œLancet. Gastroenterology & hepatology 2022 cited by 149

  13. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn’s Disease: Prospective Real-World Experience

    Authors: , , , , , , , , , , , , - Clinical Gastroenterology and Hepatology 2023 cited by 126

  14. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mercedes Cabello, Qian Cao, Flavio Caprioli, Rute Cerqueira, Baili Chen, Chou‐Chen Chen, Chou-Pin Chen, Cheng‐Tang Chiu, Chang Hwan Choi, Michele Cicala, Olena Datsenko, Pieter Dewint, Eugeni Domènech, Joris Dutré, George Duvall, J. C. Fernández, Rafał Filip, Ronald Fogel, Sharyle Fowler, Toshimitsu Fujii, Masayuki Fukata, Yohei Furumoto, Antonio Gasbarrini, Beata Gawdis-Wojnarska, Cyrielle Gilletta, Paolo Gionchetti, Eran Goldin, Oleksandr Golovchenko, Maciej Gonciarz, Can Gönen, Gaston Gonzalez Segura, Oleksii Gridnyev, T Gyökeres, Xavier Hébuterne, Charlotte Hedin, Per M. Hellström, Ida Hilmi, Ivo Horný, Gyula Horvat, Namiko Hoshi, Luděk Hrdlička, Shunji Ishihara, Olha Ivanishyn, Byung Ik Jang, Odery Junior, Takashi Kagaya, Shuji Kanmura, Marina Karakina, Nakai Katsuhiko, Jarosław Kierkuś, Hyo Jong Kim, Tae-Oh Kim, Young‐Ho Kim, G Kiss, Jochen Klaus, D Kleczkowski, Maria Kłopocka, Taku Kobayashi, Iwona Kobielusz‐Gembala, Ja Seol Koo, Adam Kopoń, Tetiana Kravchenko, Masatoshi Kudo, Kwang An Kwon, Paula Lago, David Laharie, Ian C. Lawrance, Jarosław Leszczyszyn, Yan Li, Milan Lukáš and 64 more - Gastroenterology 2023 cited by 92

  15. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation

    Authors: , , , , , , , , , , , , - Inflammatory Bowel Diseases 2019 cited by 427

  16. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook

    Authors: , , , , , , , - Gastroenterology 2015 cited by 562

  17. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation

    Authors: , , , , - Laboratory Investigation 2008 cited by 368

  18. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adam C. Ehrlich, Gary D. Wu, Loren Laine - Gastroenterology 2020 cited by 207

  19. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting

    Authors: , , , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2023 cited by 120

  20. Mediterranean-Like Dietary Pattern Associations With Gut Microbiome Composition and Subclinical Gastrointestinal Inflammation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Leo Dieleman, Brian Feagan, Anne M. Griffiths, David S. Guttman, Kevan Jacobson, Gilaad G. Kaplan, Denis O. Krause, Karen Madsen, John K. Marshall, Paul Moayyedi, Mark J. Ropeleski, Ernest G. Seidman, Mark S. Silverberg, Scott B. Snapper, Andy Stadnyk, Hillary Steinhart, Michael G. Surette, Dan Turner, Thomas Walters, Bruce A. Vallance, Guy Aumais, Alain Bitton, Maria Cino, Jeff Critch, Lee A. Denson, Colette Deslandres, Wael El-Matary, Hans Herfarth, Peter Higgins, Hien Q. Huynh, Jeff Hyams, David R. Mack, Jerry McGrath, Anthony Otley, Remo Panancionne, Guy Aumais, Robert N. Baldassano, Çharles N. Bernstein, Lee A. Denson, Colette Deslandres, Wael El-Matary, Anne M. Griffiths, Charlotte Hedin, Hans Herfarth, Peter Higgins, Séamus Hussey, Hien Hyams, Kevan Jacobson, David J. Keljo, David Kevans, Charlie W. Lees, David R. Mack, John K. Marshall, Jerry McGrath, Sanjay K. Murthy, Anthony Otley, Remo Panaccione, Nimisha Parekh, Sophie Plamondon, Graham Radford-Smith, Mark J. Ropeleski, Joel R. Rosh, David T. Rubin, Michael Schultz, Ernest G. Seidman, Corey A. Siegel, Scott B. Snapper, Hillary Steinhart, Dan Turner, Wei Xu and 1 more - Gastroenterology 2022 cited by 112

  21. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2024 cited by 120

  22. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rafał Filip, Dino Tarabar, Tkachev Av, Ursula Seidler, Eran Zittan, Juris Pokrotnieks, О. Б. Щукина, Andro Machavariani, Laura Loy, Niazy Abu-farsakh, Pesegova Marina, Slobodan Srećković, Martin Laclav, Shu‐Chen Wei, Daniel R. Suiter, A Borsuk, Xavier Hébuterne, Carsten Büning, Adi Lahat-Zok, Wit Danilkiewicz, Bernadetta Frysna, Ivana Jovicic, Olena Datsenko, Maninder Guram, Animesh Jain, Zahid Rashid, Sonja Heeren, Natallia Shulga, Ivan Timkin, Srdjan Gornjakovic, Milan Lukáš, Romain Altwegg, Ariadne Desjeux, Jean‐Marie Reimund, Manana Giorgadze, Christoph Jochum, Hiroaki Ito, Katsuhiko Nakai, Tomohisa Takagi, Osamu Zaha, Chang‐Hwan Choi, Taeoh Kim, Jong Hun Lee, Ieva Stundienė, Ida Hilmi, Rosaida Hj Md Said, Jarosław Leszczyszyn, Д. И. Абдулганиева, Yu. A. Fominykh, Svetlana V Maksyashina, Jozef Baláž, Manuel Van Domselaar, Taylan Kav, Patrick Dennis, Patricia Henry, Robert Holmes, Christopher M. Johnson, Matthew J. McBride, H Sarles, Gregory Moore, R. E. Yakubtsevich, Vinciane Muls, Stevan Trbojević, Waqqas Afif, Çharles N. Bernstein, Ivo Klarin, Zuzana Šerclová, Miroslava Volfová, Pierre Desreumaux, Cyrielle Gilletta de Saint Joseph and 46 more - ˜The œLancet. Gastroenterology & hepatology 2023 cited by 70

  23. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Simon Travis, Flávio Steinwurz, Dan Turner, Parambir S. Dulai, Vipul Jairath, Iris Dotan, María T. Abreu, Remo Panaccione, Silvio Danese - Gastroenterology 2021 cited by 165

  24. Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Crohn s and Colitis 2021 cited by 147